Pazopanib
VEGFR Inhibitor
DB06589
Approved Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
10
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.
Details
DrugBank ID
DB06589 ↗
Approval Date
2009-10-19
Molecular Weight
437.518 g/mol
Drug Class
VEGFR Inhibitor
ATC Codes
L01XE11
Synonyms
GW 78603, Pazopanibum
PubChem
CID: 10113978 ↗
ChEMBL
CHEMBL477772 ↗
SMILES
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
ADMET Profile
Computing properties…
Drug References (DrugBank)